» Articles » PMID: 27193096

Identifying Novel Therapeutic Agents Using Xenograft Models of Pediatric Cancer

Overview
Specialty Oncology
Date 2016 May 20
PMID 27193096
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

In the USA, the overall cure rate for all childhood cancers is seventy percent, and in many patients that ultimately fail curative therapy, initial responses to current multimodality treatments (surgery, radiation therapy and chemotherapy) is good, with overall 5-year event-free survival approaching 80 %. However, current approaches to curative therapy result in significant morbidity and long-term sequelae, including cardiac dysfunction and cognitive impairment. Furthermore, dose-intensive chemotherapy with conventional agents has not significantly improved outcomes for patients that present with advanced or metastatic disease. Classical cytotoxic agents remain the backbone for curative therapy of both hematologic and solid tumors of childhood. While 'molecularly' targeted agents have shown some clinical activity, responses are often modest and of short duration; hence, there is a need to identify new classes of cytotoxic agent that are effective in patients at relapse and that have reduced or different toxicity profiles to normal tissues. Here we review the pediatric preclinical testing program experience of testing novel agents, and the value and limitations of preclinical xenograft models and genetically engineered mouse models for developing novel agents for treatment of childhood cancer.

Citing Articles

Genomic profiling of subcutaneous patient-derived xenografts reveals immune constraints on tumor evolution in childhood solid cancer.

He F, Bandyopadhyay A, Klesse L, Rogojina A, Chun S, Butler E Nat Commun. 2023; 14(1):7600.

PMID: 37990009 PMC: 10663468. DOI: 10.1038/s41467-023-43373-1.


Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing.

Ghilu S, Kurmasheva R, Houghton P J Clin Med. 2021; 10(7).

PMID: 33916592 PMC: 8038510. DOI: 10.3390/jcm10071504.


Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy.

Kamili A, Gifford A, Li N, Mayoh C, Chow S, Failes T Br J Cancer. 2020; 122(5):680-691.

PMID: 31919402 PMC: 7054410. DOI: 10.1038/s41416-019-0682-4.


ΔNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma.

Cam M, Charan M, Welker A, Dravid P, Studebaker A, Leonard J Neuro Oncol. 2019; 22(3):345-356.

PMID: 31763674 PMC: 7058445. DOI: 10.1093/neuonc/noz190.


GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma.

Charan M, Dravid P, Cam M, Audino A, Gross A, Arnold M Int J Cancer. 2019; 146(11):3184-3195.

PMID: 31621900 PMC: 7440656. DOI: 10.1002/ijc.32743.


References
1.
Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner E, Wolff B . Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A. 1999; 96(16):9112-7. PMC: 17741. DOI: 10.1073/pnas.96.16.9112. View

2.
Thompson J, George E, Poquette C, Cheshire P, Richmond L, de Graaf S . Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res. 1999; 5(11):3617-31. View

3.
Teitz T, Wei T, Valentine M, Vanin E, Grenet J, Valentine V . Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med. 2000; 6(5):529-35. DOI: 10.1038/75007. View

4.
Du C, Fang M, Li Y, Li L, Wang X . Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000; 102(1):33-42. DOI: 10.1016/s0092-8674(00)00008-8. View

5.
Chai J, Du C, Wu J, Kyin S, Wang X, Shi Y . Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature. 2000; 406(6798):855-62. DOI: 10.1038/35022514. View